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a  b  s  t  r  a  c  t
Bariatric  surgery  for obesity  has  proved  to  be an  extremely  effective  method  of promoting  long-term
weight  reduction  with  additional  beneﬁcial  metabolic  effects,  such  as improved  glucose  tolerance  and
remission  of  type  2  diabetes.  A  range  of bariatric  procedures  are  in common  use,  including  gastric  band-
ing,  sleeve  gastrectomy  and  the  Roux-en-Y  gastric  bypass.  Although  the  mechanisms  underlying  the
efﬁcacy  of bariatric  surgery  are  unclear,  gastrointestinal  and pancreatic  peptides  are  thought  to  play  an
important  role.  The  aim  of  this  review  is to summarise  the  effects  of different  bariatric  surgery  proce-eywords:
ariatric
hrelin
astrin
holecystokinin
ncretin
dures  upon  gastrointestinal  and pancreatic  peptides,  including  ghrelin,  gastrin,  cholecystokinin  (CCK),
glucose-dependent  insulinotropic  hormone  (GIP),  glucagon-like  peptide  1 (GLP-1),  peptide  YY (PYY),
oxyntomodulin,  insulin,  glucagon  and  somatostatin.
©  2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).xyntomodulin
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. Introduction
Obesity, deﬁned as a body mass index over 30 kg/m2, is con-
idered one of the greatest public health challenges of our time
1]. Obesity is associated with multiple metabolic comorbidities,
ncluding type 2 diabetes. Bariatric surgery, which aims to pro-
ote weight loss by either reducing stomach size or bypassing a
ortion of intestine, is associated with effective long-term weight
oss and beneﬁcial metabolic sequelae [2]. The mechanisms which
nderlie these consequences of bariatric surgery remain unclear,
ut they are likely to include effects upon peptide hormones, partic-
larly gut-derived peptides [3]. The aim of this review is to describe
he different bariatric procedures available and their known effects
pon peptide hormones.
. Bariatric surgery procedures
A wide range of surgical procedures have been used to promote
eight loss since bariatric surgery was initially developed in the
950 s. In general, bariatric procedures act by reducing the size or
apacity of the stomach, by bypassing a portion of the intestine or
y a mixture of these two approaches. The most commonly used
rocedures at present are gastric banding, sleeve gastrectomy and
he Roux-en-Y gastric bypass (Fig. 1).
.1. Gastric banding
Gastric banding was ﬁrst introduced in the 1970 s and involves
he placement of a silicone ring around the stomach to create a
mall upper gastric pouch at the bottom of the oesophagus. This
rocedure is safe, well tolerated and efﬁcacious with a low risk of
erious complications such as malabsorption. The band needs to be
djusted intermittently to optimise weight loss and to minimise
omplications.
.2. Sleeve gastrectomy
The sleeve gastrectomy involves creating a long, thin gas-
ric pouch or sleeve by stapling the stomach longitudinally. This
educes the volume of the stomach but leaves the pylorus intact.
he sleeve gastrectomy was initially performed as a precursor to
 larger procedure but has been increasingly used alone due to
ts efﬁcacy. Sleeve gastrectomy is now one of the most commonly
erformed bariatric surgery procedures.
.3. Roux-en-Y gastric bypass
The Roux-en-Y gastric bypass (RYGB) is the most commonly
erformed bypass procedure. It involves the creation of a small
astric pouch which is drained into the jejunum (alimentary limb)
ith no contact between nutrients and the pylorus and duode-
um. The bile and pancreatic juices drain into the duodenum and
ejunum as normal (biliopancreatic limb) but are only mixed with
ood after the anastomosis of the alimentary and biliopancreatic
imbs to create the common limb. The length of the common limb
s important in determining the likely risk of serious malabsorp-
ion and related nutrient deﬁciencies (discussed elsewhere [4]).
n standard RYGB, the Roux limb is usually 0.75–1.5 metres long
ith a common limb of ∼3 m which is adequate for absorption of
acronutrients and micronutrients. A ‘distal bypass’ technique has . . . . . . . . . . .  . . .  . . . . .  . . . . .  . . . . .  . . .  .  . . . .  . . .  . . .  . .  . .  .  . . . .  . . .  .  .  .  . . . .  .  . . . . .  . . . . .  . . . 35
been used which reduces the common limb to ∼75 cm but carries
a greater risk of nutrient deﬁciencies [5]. Although the RYGB has
been widely used for successful weight loss, it can cause dumping
syndrome, due to the lack of pyloric control over gastric empty-
ing. Dumping syndrome occurs when a high osmolar load reaches
the intestine rapidly, prompting ﬂuid to enter the gut lumen and
causing hypovolaemia, abdominal distension, nausea, vomiting,
diarrhoea, dizziness and fatigue. In some patients, hypoglycaemia
can also occur due to the strong insulin response which is likely to
be stimulated by incretins upon exposure of the ileum to ingested
nutrients.
3. The effects of bariatric surgery upon gut peptides
Many of the beneﬁcial metabolic effects of bariatric surgery have
been attributed to altered peptide hormone proﬁles, especially
involving pancreatic and gut peptides. However, other mechanisms
are also likely to have a role, but are beyond the scope of this review.
The absorption and digestion of nutrients requires a healthy gas-
trointestinal tract which is subject to the control by nervous and
hormonal inﬂuences. Several gut hormones are responsible for reg-
ulating appetite and satiety and also control the movement of the
gut and hence transit of food through the intestines (see Table 1).
4. Changes in speciﬁc gut hormones following bariatric
surgery
4.1. Gastrin
Gastrin is produced in enteroendocrine G cells which predom-
inate in the gastric antrum and duodenum and is released in
response to food and gastric distension. It acts to increase the
secretion of hydrochloric acid, pepsinogen and pancreatic juices
and reduces appetite. Secretion appears to be highest when nutri-
ents are in direct contact with the G cells. Rather than being a
single molecular entity, gastrin is actually a family of multiple pep-
tides of varying length with varying degrees of biological activity.
Measuring and quantifying gastrin activity in a meaningful way  is
challenging because of this structural heterogeneity.
Theoretically, procedures (such as the RYGB) which exclude the
gastric antrum or duodenum reduce contact between the nutri-
ents and the majority of the G cells and would be likely to cause
a fall in gastrin secretion. Ongoing production of hydrochloric acid
in the gastric remnant without the buffering effect from ingested
nutrients stimulates the production of secretin and somatostatin
which further inhibit gastrin secretion. Indeed, there is some evi-
dence that postprandial gastrin levels fall after RYGB both in the
ﬁrst two  weeks post-operatively [6] and over the ﬁrst year [7]. It has
recently come to light that the remnant stomach is subject to multi-
ple histological changes following RYGB. Common changes include
chronic gastritis and atrophic gastritis. One study has demonstrated
an increased proliferation rate in the epithelium of the excluded
gastric antrum coupled with a reduction in the number of G cells
[8]. It has been suggested that excessive gastric acid production may
be involved in the pathogenesis of abnormal histological ﬁndings in
the stomach after RYGB [9]. The role of gastrin secretion as either
a cause or consequence of altered gastric histology is unclear. In
clinical practice, many patients commence proton pump inhibitor
therapy post-operatively which reduces gastric acid production,
increases gastrin and prevents acid- related complications.
30 C.L. Meek et al. / Peptides 77 (2016) 28–37
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Other procedures where the G cells are still exposed to nutrients
ay  be associated with different effects. A study in 24 patients with
astric banding demonstrated no change in fasting gastrin concen-
rations 6–12 months after surgery [10]. There have been reports
hat the gastric sleeve may  be associated with increased gastrin
evels in both human and animal studies [11,12]. The reasons for
his are unclear.
.2. Ghrelin
Ghrelin is produced in the stomach and pancreas in response
o fasting and is associated with hunger. Ghrelin is usually consid-
red to be most active in its acylated form, with an octanoyl group
ttached to its third amino acid residue, which occurs due to the
ction of ghrelin-O-acyltransferase (GOAT). Acylated ghrelin is then
ble to activate the growth hormone secretagogue receptor (GHSR)
hich is predominantly found in the hypothalamus and pituitary
lands [13]. Acylated ghrelin is orexigenic. In obesity, both fast-
ng and postprandial total ghrelin concentrations are lower than in
ormal weight individuals but the proportion of acylated ghrelin is
igher in the obese [14].
Ghrelin levels rise with prolonged fasting and fall after a meal.
herefore, in general, weight loss via calorie restriction increases
hrelin levels, a phenomenon which may  contribute to the poor
ong-term efﬁcacy of dietary manipulation to control obesity [15].
he short and long-term effects of bariatric surgery upon ghrelin
evels are still unclear, and most studies have involved relatively
ew participants. Different bariatric procedures appear to have
ifferent effects upon ghrelin secretion, possibly due to anatom-
cal variations changing the degree of contact between ingested
utrients and the mucosa of the gastric fundus where the ghrelin
roducing cells are predominantly located. Gastric banding appears
o be associated with an increase in ghrelin levels. Fruhbeck and
oworkers [16] studied 24 obese men  who had similar degrees of
eight loss following adjustable gastric banding (GB; n = 8), RYGB
n = 8) or conventional dietary management [8]. 6 months after
urgery ghrelin levels were increased to a similar degree in both
he GB and conventional dietary management groups. Patients withriatric surgery procedures.
RYGB had a signiﬁcant decrease in ghrelin levels after 6 months, an
effect which was comparable to that seen post-gastrectomy (n = 6).
The authors concluded that the RYGB reduced ghrelin levels due to
the exclusion of the gastric fundus, with reduced or absent contact
between ghrelin-producing mucosal cells and ingested nutrients
[16,17]. Similar effects have been seen by other groups. Jacob-
sen et al., found that fasting and postprandial ghrelin levels fell
2 weeks after RYGB [6]. Cummings and coworkers noted that gas-
tric bypass (n = 5 patients) obliterated normal ghrelin diurnal and
post-prandial ﬂuctuations and was  associated with a reduction in
24-h ghrelin area under the curve when compared to 5 healthy
obese matched controls and 10 controls of normal weight. Similar
results have been shown elsewhere [18]. There is some evidence
that the effects of RYGB upon ghrelin are important for the efﬁ-
cacy of the operation in terms of promoting and sustaining weight
loss. Dirksen et al., studied 33 patients for 12 months after RYGB
and found that those who had a good weight loss response (good
responders) had a higher degree of ghrelin suppression compared
to poor responders [19]. However, not all studies have been able to
replicate a suppressant effect of RYGB on ghrelin in human or ani-
mal  work [7,20,21]. Interestingly, sleeve gastrectomy may  decrease
circulating acylated ghrelin concentrations [22], possibly due to the
removal of ghrelin-producing cells in the stomach.
4.3. Cholecystokinin (CCK)
CCK is secreted by I cells in the duodenal mucosa and acts to
promote contraction of the gallbladder which propels bile into the
gut lumen. It also promotes the release of digestive enzymes from
the pancreas, slows gastric emptying and is associated with satiety.
Several studies have shown an increase in CCK levels postprandi-
ally after RYGB in response to a mixed meal [6,19]. This is perhaps
surprising, since the main physiological stimulant of CCK release
is the presence of amino acids and fatty acids within the duo-
denum, which is excluded from contact with nutrients following
RYGB. However, there are other stimulants of CCK release, such
as parasympathetic impulses and intra-luminal releasing factors
which may  be important following bariatric surgery [23]. Another
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Table  1
A summary of peptide hormones which act upon the gut and their likely roles.
Hormone Site of
production
Stimulus for
secretion
Likely actions
Gastrin G cells in the
gastric antrum
and duodenum
Gastric
distension &
food in the
stomach
• Increases production of hydrochloric acid, pepsinogen,
intrinsic factor, pancreatic secretions and bile.
• Promotes satiety
Ghrelin Predominantly
stomach and
pancreas.
Empty stomach • Stimulates appetite, increases hunger
•  Increases gastric emptying and gastrointestinal motility
in preparation for eating
• Induces growth hormone release
• Inhibits glucose-stimulated insulin production
Cholecystokinin
(CCK)
I  cells in
duodenal
mucosa
Fatty acids or
amino acids in
the duodenum
• Contraction of the gallbladder releasing bile
•  Pancreatic enzyme secretion
•  Secretion of insulin, glucagon and PP
• Slows gastric emptying
• Promotes satiety
Secretin S cells in
duodenal
mucosa
Low pH in the
lumen
• Increases production of pancreatic bicarbonate
•  Reduces gastric acid production and inhibits gastrin
release
• Promotes insulin release
• Reduces gastric and duodenal motility
Vasoactive
intestinal
polypeptide
(VIP)
Enteric nerves
and parasym-
pathetic
efferent nerve
ﬁbres
Vagal
stimulation
• Increases the secretion of water and electrolytes out of
cells and into the gut lumen
• Relaxation of smooth muscle in the vasculature, gut and
genitourinary system.
• Reduces gastric acid production
• Promotes hormone release from the pancreas, gut and
hypothalamus
Pancreatic
polypeptide
(PP)
Produced by PP
cells in the
pancreas
Meal,
especially high
protein
content.
• Regulates production of both exocrine and endocrine
pancreatic secretions
• Associated with satiety.
Gastric
inhibitory
peptide (GIP)
K cells in the
gastrointestinal
mucosa (ileum)
Nutrients in
the gut lumen
• Incretin hormone, promoting insulin production and
release in the pancreas
• Promotes satiety
• Promotes a postprandial rise in glucagon
•  Prevents beta cell apoptosis
• Promotes the conversion of glucose to fatty acids and
their storage in adipose, by increasing the activity of
lipoprotein lipase.
Glucagon-like
peptide -1
(GLP-1)
L cells in the
gastrointestinal
mucosa (ileum)
Nutrients in
the gut lumen
• Incretin hormone, promoting insulin production and
release in the pancreas
• Reduces gastric emptying and intestinal motility
• Promotes satiety
Glucagon-like
peptide -2
(GLP-2)(99)
L cells in the
gastrointestinal
mucosa (ileum)
Nutrients in
the gut lumen
• Promotes gut hypertrophy
• Possible role in glucose homeostasis
•  Possible role in slowing gut motility to promote
absorption
Oxyntomodulin L cells in the
gastrointestinal
mucosa (ileum)
Nutrients in
the gut lumen
• Promotes satiety
• Agonist of glucagon receptor and GLP-1 receptors
•  Increases energy expenditure
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cPeptide YY
(PYY)
L cells in the
gastrointestinal
mucosa (colon)
Nutrient
the gut lu
ossible explanation is that surgery may  increase stimulation of
CK cells in the more distal small intestine or alter the number
f CCK-producing cells within duodenal mucosa [24,25] leading to
igher CCK production for a given level of stimulus.
The role of CCK in the efﬁcacy of bariatric surgery is unclear.
heoretically, high CCK levels may  contribute to the increased sati-
ty and improved glucose homeostasis following RYGB. However,
irksen et al., found that CCK levels were higher in poor responders
ompared to good responders after RYGB [19].• Promotes satiety
• Reduces gastric emptying and intestinal motility
• Ileal brake
Few studies have examined the changes in CCK which occur
following other bariatric procedures. Peterli et al. [26] assessed
patients up to 1 year after RYGB or sleeve gastrectomy. While both
groups showed increased postprandial CCK levels compared to pre-
operative concentrations, the sleeve gastrectomy was associated
with a much larger CCK increase compared to the RYGB group. This
difference was evident at one week post-operatively, and gained in
magnitude over the ﬁrst year [26]. The effect of gastric banding on
CCK concentrations is unknown.
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.4. GIP
Glucose-dependent insulinotropic polypeptide (GIP) is secreted
rom K cells in the small intestine. Like GLP-1, GIP is associated with
n insulinogenic effect following ingestion of oral glucose (histori-
ally this has been known as the incretin effect). GIP was  originally
alled gastric inhibitory polypeptide and was ﬁrst identiﬁed as a
actor which dramatically inhibited gastric acid secretion in dogs.
owever, this effect was found to be negligible in humans and
he hormone was later renamed glucose-dependent insulinotropic
olypeptide (GIP) [27]. The role of GIP in the development of
iabetes and obesity is unclear, but hyperglycaemia may  act to
irectly downregulate GIP receptors in pancreatic -cells [28] lead-
ng to a defect in late-stage insulin release [29,30]. GIP is secreted
rom K cells found throughout the small intestine but in highest
roportions in the duodenum and jejunum [27]. Bariatric proce-
ures which reduce or prevent nutrient exposure to the duodenum
nd jejunum, such as the RYGB, have been found in some stud-
es to result in a reduction in postprandial GIP secretion [31],
n effect which may  be more pronounced in diabetic subjects
32,33]. Reductions in fasting GIP have also been found after surgery
34] but reduced fasting or postprandial GIP levels have not been
escribed in all reports [6,35,36]. Altered fasting and postprandial
IP responses to bariatric surgery may  be affected by the presence
r absence of diabetes [35–37].
The role of GIP in other procedures is even less clear. After gastric
anding, there appears to be no change in fasting GIP concentra-
ions 6–12 months after surgery [10,38], however, postprandial GIP
evels may  be reduced [38].
.5. GLP-1
Glucagon-like peptide 1 (GLP-1) is secreted from L cells
hich predominate in the distal ileum and colon. Although fast-
ng concentrations of GLP-1 do not appear to change markedly
fter bariatric surgery [10,39], there is a large body of evidence
uggesting that postprandial levels are increased compared to
he pre-surgical state following many different bariatric proce-
ures including gastric banding, sleeve gastrectomy and RYGB
6,19,22,40]. The reasons for this sustained increase in GLP-1 post-
urgery are unclear but have been attributed to the greater delivery
f intact nutrients to the ileum through anatomical changes or
ncreased intestinal transit (hindgut hypothesis) [41–44]. An alter-
ative hypothesis, the foregut hypothesis, suggests that exclusion
f the upper small intestine is responsible for the beneﬁcial aspects
f bariatric surgery, possibly through decreased secretion of an
anti-incretin’ factor [37,45,46].
The beneﬁcial effects of bariatric surgery upon appetite and
lucose homeostasis have been attributed, at least in part, to the
ncreased secretion of GLP-1. GLP-1 is an attractive candidate for
his role as potential mediator of these beneﬁcial effects as it
s an incretin hormone and has an insulinogenic effect follow-
ng ingestion of oral glucose [47]. Binding of GLP-1 to the GLP-1
eceptor on pancreatic beta cells activates adenylate cyclase and
ncreases cAMP concentrations which augment glucose-dependent
nsulin secretion. The ability of GLP-1 to promote insulin secre-
ion is dependent upon the glucose concentration, with reduced or
bsent effect at low glucose concentrations. This has made GLP-
 agonists an attractive target for pharmacological intervention
o reduce hyperglycaemia with no undue tendency for hypogly-
aemia. GLP-1 agonists or mimetics such as liraglutide have been
pproved for pharmacological use in the treatment of diabetes and
besity [49,50].
GLP-1 is also thought to have centrally-mediated effects
pon appetite by interacting with vagal afferent nerve ﬁbres. In
odents, GLP-1 administration appears to activate neurones in the 77 (2016) 28–37
brainstem, including the arcuate nucleus and paraventricular
nucleus to promote satiety [51–53]. Performing a vagotomy with
bariatric surgery attenuates these effects [51]. There is also some
evidence to support an increase in energy expenditure in rodents
[19,53] but this is less clear in humans [19]. GLP-1 may  also medi-
ate altered food choices, for example, with increased palatability
of less calorie-dense foods in rats [54,55] but work in humans has
shown fewer clear effects [54].
Although GLP-1 is widely believed to account for at least some
of the beneﬁcial effects of RYGB upon weight and glucose toler-
ance [56], it is unlikely to account for all of the effects. Jorgensen
et al., found that the beneﬁcial metabolic effects of RYGB upon beta-
cell sensitivity were obliterated by infusion of exendin-9, a GLP-1
receptor antagonist (GLP1R) [57] suggesting that GLP-1 action is
fundamental in achieving improved glucose tolerance after surgery.
There is also some evidence that GLP-1 concentrations may  be
directly related to a patient’s individual outcome following bariatric
surgery. In their study of 33 patients for one year after RYGB,
Dirksen et al., found that levels of GLP-1 were higher in patients
who had lost large amounts of weight post-surgery (good respon-
ders) compared to those with poor weight loss (poor responders)
[19]. However, Wilson-Pérez et al., found that sleeve gastrectomy
was still effective in GLP-1 receptor knockout mice suggesting that
the GLP-1 receptor is not necessary for beneﬁt and that alterna-
tive pathways must also be involved [58]. Mokadem et al., found
that RYGB has beneﬁcial metabolic effects in two mouse models
of GLP-1 deﬁciency, and that the results were comparable to RYGB
treated control mice [59]. Taken together, this evidence suggests
that while GLP-1 may  have a role in promoting the beneﬁcial effects
of bariatric surgery upon metabolic health, other mechanisms are
also likely to play a role and GLP1R agonism alone is not responsible
for the complete effect.
One proposed mechanism of action is that the beneﬁcial effects
of GLP-1 are mediated through altered gastric motility. Physiologi-
cally and pharmacologically, GLP-1 and GLP-1 mimetics have been
associated with delayed gastric emptying [60,61], resulting in a
more gradual supply of nutrients to the gut, a phenomenon which
has been linked to improved glucose tolerance [62]. However, there
is some evidence from human studies that GLP-1 may  actually be
associated with increased gastric transit for liquid calories [44].
A second possible mechanism is that GLP-1 and GIP promote
diabetes remission due to their functions as incretin hormones
[56]. The incretin effect is the ability of intra-intestinal glucose
to stimulate greater insulin production than a similar quantity
of intra-venous glucose, and has been attributed to the direct
insulinotropic effects of GLP-1 and GIP. In fact, these incretin hor-
mones are likely to account for at least 50% of the postprandial
insulin response in humans and animals and appear to be particu-
larly important for the ﬁrst phase insulin response [63,64].
However, while the incretin effect might account for the
improved glucose tolerance after bariatric surgery, increased
insulin secretion might be expected to produce weight gain, rather
than weight loss. Although GLP-1 is associated with satiety, its
role in promoting weight loss following bariatric surgery remains
poorly understood.
4.6. GLP-2
L cells are also capable of secreting glucagon like peptide 2 (GLP-
2) which is much less clearly understood compared to GLP-1. GLP-
2 appears to have a role in stimulating gut hypertrophy by ileal
cell hyperplasia and reducing apoptosis [65] and has been used
therapeutically in patients with short gut syndrome [66].
Following bariatric surgery, concentrations of GLP-2 appear to
be increased in rodents and humans [67,68]. Le Roux et al., found
that this increase in GLP-2 was  accompanied by crypt cell prolifer-
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tion [67]. However, other studies have failed to show any effect of
ariatric surgery upon GLP-2 [69].
.7. PYY
Like GLP-1, PYY1–36 is produced by enteroendocrine L cells in
he distal small intestine and colon. Following cleavage in the cir-
ulation by the enzyme dipeptidyl-peptidase-IV (DPP-IV), PYY1–36
s converted to PYY3–36 which is considered to promote satiety
hrough its agonism of the Y2 receptor [70]. Although PYY3–36 has
any effects upon the body including delaying gastric emptying
71], reducing postprandial insulin production [71] and altering
olonic motility [72], its main role appears to involve the central
egulation of appetite [73]. Observations that postprandial PYY3–36
evels appear to be reduced in obese patients compared to healthy
olunteers and that PYY3–36 infusion reduces caloric intake have led
o suggestions that obesity is a state of PYY3–36 deﬁciency [73,74].
Following bariatric surgery, levels of PYY increase postpran-
ially, an effect which is evident two weeks post-surgery and
till present after a year [6,75]. This increase in postprandial PYY
ppears to occur following many different types of bariatric pro-
edure including gastric banding [76], sleeve gastrectomy [40] and
YGB [75]. Rodent knockout models suggest that PYY is an impor-
ant contributor to weight loss following bypass surgery [77].
.8. Oxyntomodulin
Oxyntomodulin and glicentin are additional L cell products
hich, like GLP-1, originate from the proglucagon gene by alter-
ative post-translational processing pathways. Oxyntomodulin is
 37-amino acid peptide hormone which is structurally similar to
lucagon with an additional C-terminal octapeptide. However, very
ittle is known about the role of oxyntomodulin in bariatric surgery.
aferrère et al., studied ten obese women with type 2 diabetes
efore and 1 month after RYGB who were matched with ten women
ho achieved 10 kg of weight loss through dietary means. Patients
ho had the RYGB demonstrated a marked increase in oxyntomod-
lin levels following a 50 g glucose test meal. Fasting levels were
imilar in the surgical and diet-induced weight loss groups [78].
ther studies have shown similar ﬁndings [79]. However, the role
f oxyntomodulin in the aetiology of weight loss in other bariatric
urgery procedures is still to be elucidated.
Oxyntomodulin appears to be an agonist on both GLP-1 recep-
ors (GLP1R) and glucagon receptors (GCGR) and is considered to
e a promising pharmacological agent in the treatment of obesity.
odent studies conﬁrm that the dual agonism upon GLP1R and
CGR is responsible for more potent metabolic effects compared
o GCGR or GLP1R agonism alone [80]. This has given rise to further
ork identifying alternative GLP1R–GCGR co-agonists with struc-
ural similarities [81]. As a weight loss agent, Oxyntomodulin has
hown promise in both rodent and human studies. Subcutaneous
dministration of oxyntomodulin over 4 weeks promotes weight
oss in humans and appears to be associated with both an increase
n energy expenditure and reduction in food intake with no change
n food palatability [82,83].
.9. Other gut hormones
There are several other gut hormones which may  be involved in
ediating the effects of bariatric surgery, or which may  be altered
n secretion rates or function following gastrointestinal surgery.
ecretin is a 27 amino acid peptide hormone which is produced
y S cells in the duodenal mucosa in response to a low intralu-
inal pH. It works to promote pancreatic bicarbonate production
nd reduce the production of gastric acid. Vasoactive intestinal
olypeptide (VIP) is a 28 amino acid peptide released by the enteric 77 (2016) 28–37 33
nervous system and parasympathetic efferent nerve ﬁbres, which
acts to increase the secretion of water and electrolytes into the
pancreatic juices and the gut itself. It also causes relaxation of gas-
trointestinal smooth muscle and reduces the production of gastric
acid. Pancreatic polypeptide (PP) is a 36 amino acid peptide hor-
mone, production of which is normally attributed to PP cells in the
pancreas, but also likely involves gut endocrine cells. It acts to reg-
ulate both exocrine and endocrine pancreatic activities via central
mechanisms following the ingestion of a meal, especially a high
protein meal. PP is thought to play a role in satiation following
the observation that infusing PP to human volunteers resulted in
a reduction in food intake [6]. Unfortunately very little is known
about the effect of bariatric surgery upon these hormones Table 2.
4.10. Insulin
Insulin is a 51-amino acid peptide hormone produced in the
pancreatic beta cells which reduces blood glucose concentrations
postprandially. Type 2 diabetes mellitus is a disorder of deﬁcient
insulin release, often developing in obese individuals who have
increased insulin requirements resulting from obesity. Different
bariatric procedures have different effects upon insulin secretion.
Shak et al., found that fasting insulin levels were unchanged after
gastric banding [10]. RYGB and sleeve gastrectomy both seem to
have more pronounced effects upon insulin. Mallipedhi et al., found
that fasting insulin levels fell one and six months after sleeve gas-
trectomy [84]. Insulin concentrations also appear to fall after RYGB,
an effect which appears to be accompanied by an increase in insulin
sensitivity, as measured by the homeostasis model assessment
score (HOMA) [79]. Although many studies have demonstrated an
increase in insulin sensitivity with the RYGB [6,79,85], there also
appears to be evidence of improved beta cell function [85,86]. Jor-
gensen and coworkers studied 13 patients with obesity and type
2 diabetes following RYGB surgery. Within one week post-surgery,
there was  a signiﬁcant reduction in fasting insulin and glucose with
improvements in beta-cell sensitivity [86], effects which have been
attributed to the beneﬁcial effects of GLP-1 [57].
The ability of bariatric surgery to cause remission or cure of
diabetes is presumably related to its ability to improve insulin
sensitivity and beta cell function, but the precise mechanisms
are imperfectly understood. Undoubtedly, some of the beneﬁt of
bariatric surgery on insulin and glucose homeostasis is mediated
by weight loss. Indeed, Lim et al., demonstrated that a calorie-
restricted diet of 600 kcal/day has the ability to normalise fasting
glucose concentrations and improve the ﬁrst phase insulin secre-
tion in a group of non-surgical patients with type 2 diabetes
[87]. Although all forms of bariatric surgery have the potential to
exert beneﬁcial effects upon glucose tolerance through weight loss,
some procedures, particularly RYGB, are associated with greater
improvements in metabolic health than can be explained by weight
loss alone [88]. Other procedures, such as gastric banding, have
more modest effects upon insulin and glucose which might be
explained by weight loss alone [10]. Other studies have found sim-
ilar beneﬁcial effects upon glucose tolerance following RYGB in
non-diabetic subjects [6].
Many studies report different remission rates according to the
deﬁnitions used [89]. Pories et al., reviewed 298 patients with pre-
existing impaired glucose tolerance or type 2 diabetes. Following
RYGB, 91% of these patients attained normal glucose tolerance,
an effect which persisted for many years for the majority or
patients [88]. The achievement of normal glucose tolerance for 1
year without the assistance of active pharmacological therapy or
other ongoing procedures is consistent with remission of diabetes,
according to the American Diabetes Association (see Table 3) [90].
Short-term, RYGB is associated with around 52% remission of
type 2 diabetes. Sleeve gastrectomy is associated with 26% remis-
34 C.L. Meek et al. / Peptides 77 (2016) 28–37
Table 2
Effects of bariatric surgery procedures upon gut peptides.
Hormone Obesity
(without
surgery)
Gastric banding Sleeve
Gastrectomy
Roux-en-Y gastric
bypass
Gastrin (7, 10–12) ↔ ↑ ↓ postprandial
Ghrelin  (total) (6, 7,
14, 16–19, 22, 100,
101)
↔ or ↓ fasting
↔ or ↓
postprandial
↑ ↓ fasting
↓ postprandial
↓ fasting
↓ postprandial
Cholecystokinin
(CCK)  (6, 19, 26,
101)
↔ fasting
↔ or ↓
postprandial
↔ fasting
↑postprandial
↔ fasting
↑postprandial
Gastric inhibitory
peptide (GIP) (10,
31, 38, 84)
↔ ↔ fasting
↔ or ↓
postprandial
↑ postprandial ↔ or ↓ fasting
↔ or ↓
postprandial
Glucagon-like
peptide -1 (GLP-1)
(6, 19, 22, 40)
↔ or ↓ ↔ or slight ↑
fasting Slight
↑postprandial
↔ or slight ↑
fasting
↑postprandial
↔ or slight ↑
fasting
↑postprandial
Glucagon-like
peptide -2
(GLP-2)(67, 69)
↑ postprandial ↔ or ↑
postprandial
Peptide YY (PYY)
(6, 73, 74, 76, 77)
↓ ↔ or slight ↑
fasting
Slight
↑postprandial
↔ or slight ↑
fasting
↑postprandial
↔ or slight ↑
fasting
↑postprandial
Oxyntomodulin(78) ↔ fasting
↑postprandial
Insulin (86, 102) ↔,  ↑ or ↓
depending on
diabetes status
↔ fasting ↓ fasting
↔ or ↓
postprandial
↓ fasting
↔ or ↓
postprandial
Glucagon (85, 95,
96)
↔ or ↑ ↑or ↓ fasting
↔ or ↓
postprandial
Somatostatin (6) ↑ fasting
↑ postprandial
Note that this information is based upon several studies but many areas are controversial and studies have had conﬂicting results. The table below aims to give a summary
of  the most consistent patterns. Cells were left blank if evidence was lacking.
Table 3
deﬁnitions of diabetes status after bariatric surgery(90).
Deﬁnition Criteria
Improved
diabetic
control
• A signiﬁcant reduction in A1C (by >11 mmol/mol or 1%) or
•  A signiﬁcant reduction in fasting blood glucose (by >1.4 mmol/l or 25 mg/dL)
or
•  A signiﬁcant reduction in A1C and FBG accompanied by a decrease in
antidiabetic medication requirement
• At least 1year’s duration
Partial
remission
•  Hyperglycemia below diagnostic thresholds for diabetes (HbA1c
42–47 mmol/mol; fasting glucose 100–125 mg/dL (5.5–6.9 mmol/))
•  At least 1 year’s duration
•  No active pharmacologic therapy or ongoing procedures
Complete
remission
•  Normal glycemic measures (HbA1c <48 mmol/mol; fasting glucose
<125 mg/dl (7.0 mmol/l))
• At least 1 year’s duration
going
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t•  No active pharmacologic therapy or on
Prolonged
remission
•  Complete remission of at least 5 years’
ion and gastric banding with 6% remission of type 2 diabetes [91].
mong patients who do not achieve complete remission, many
chieve partial remission or an improvement in their diabetic con-
rol (Table 3) or improved quality of life [92]. Of patients following
YGB, sleeve gastrectomy and gastric banding respectively, 1%, 4%
nd 31% have unchanged glucose tolerance [91]. Bariatric surgery
lso reduces the likelihood of a future diagnosis of diabetes com-
ared to matched controls [93]..11. Glucagon
Glucagon is a 29 amino acid peptide hormone produced in
he alpha cells of the pancreatic islets. It is released during the procedures
ion
fasting state and acts to increase blood sugar levels by promot-
ing glycogenolysis and gluconeogenesis. In general, weight loss
leads to reduced circulating concentrations of glucagon [94]. Very
few studies have assessed the effect of bariatric surgery upon cir-
culating glucagon concentrations. Korner et al., studied glucagon
concentrations in women  after gastric banding, RYGB and in a
group of overweight control patients (n = 36 in total) [95]. Patients
were studied at around 24 months post-surgery and were weight
stable at the time of the study. The investigators found no differ-
ence between fasting glucagon and area under the curve from 0 to
180 min  after a liquid meal, but glucagon concentrations at 180 min
were signiﬁcantly lower in patients who had the RYGB compared
to the control group. However, different groups have found dif-
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erent effects of surgery upon glucagon concentrations. Umeda
t al., studied patients before and up to 3 months after RYGB. Fast-
ng glucagon concentrations increased and postprandial glucagon
evels decreased following surgery in response to a liquid meal
85]. Conversely, Swarbrick et al., found low fasting glucagon levels
fter surgery but their data suggests that reductions in circulating
lucagon occur in a gradual manner and only became signiﬁcantly
ifferent to baseline levels at three months [96]. It is unclear if this
eduction occurred independently of weight loss.
.12. Somatostatin
Somatostatin is peptide hormone produced by delta (or D)
ells in the pancreas, stomach and duodenum. The preprohormone
an be cleaved at two different locations giving two  forms of 14
nd 28 amino acids in length which both have biological activity.
omatostatin regulates the secretion of multiple other hormones.
n the gastrointestinal tract, it reduces the secretion of gastrin,
ecretin, CCK, GIP and GLP-1. In the pituitary, it reduces secretion
f growth hormone, thyroid stimulating hormone and prolactin.
n the pancreas, it reduces production and secretion of insulin and
lucagon and inhibits exocrine secretion. A somatostatin analogue,
ctreotide, has been found to cause reduced adiposity in rats fed a
igh-fat diet [97]. A human study has suggested that somatostatin
nfusion inhibits release of PYY in obese women [98].
The role of somatostatin following bariatric surgery is unclear.
acobsen et al., found that fasting and postprandial levels of
omatostatin in venous blood were unchanged in 8 obese non-
iabetic patients two weeks after undergoing RYGB [6]. However,
s somatostatin exerts some of its actions in a paracrine manner,
irculating venous concentrations may  not adequately represent
ltered physiological actions, and two weeks may  be too early to
ee any effect. The contribution of gastrointestinal somatostatin
ecretion to circulating somatostatin concentrations is also unclear.
ther reports have suggested that an older procedure, jejunoileal
ypass, affects somatostatin cell density [25].
. Conclusions
Bariatric surgery remains the only treatment with proven effect
t inducing rapid and sustained weight loss with related beneﬁ-
ial metabolic effects such as remission of type 2 diabetes. A range
f different surgical approaches have been attempted in the past,
ut current practice centres around gastric banding, sleeve gastrec-
omy and RYGB.
Studies of peptide hormone concentrations after bariatric
urgery have often found conﬂicting results. This may  in part relate
o differences of timing after the procedure, as it may  take up to
 year or more to reach a steady state (for example, [96]). Weight
oss itself can cause changes in peptide hormone secretion, even
n the absence of bariatric surgery [87] and it is difﬁcult to evalu-
te the effects of surgery independently of weight loss in the initial
onths after surgery. Many studies measure either fasting or post-
randial concentrations of hormones and a wide variety of meal
ests have been used in the literature. It is quite likely that different
eal tests will have slightly different effects upon hormone secre-
ion due to different nutrient composition. Assays for many peptide
ormones are challenging due to the structural heterogeneity of
he molecules. A range of different assays are in use for measuring
eptide hormone concentrations and this may  also contribute to
he differences between studies.The beneﬁcial effects of bariatric surgery are still poorly under-
tood, but are most likely to be multifactorial in aetiology. Increases
n satiety-promoting hormones, reductions in hunger-promoting
ormones, reduced food intake (at least in the early post-surgery
[
[ 77 (2016) 28–37 35
phase), central effects, altered bile acid metabolism and altered
intestinal microbiota may  all play a role. Indeed, weight loss itself
is associated with beneﬁcial metabolic effects [87] and altered gut
hormone secretion but bariatric surgery appears to create circum-
stances where weight loss can be maintained in the long term.
The effect of bariatric surgery upon glucose tolerance is likely
to be related to increased production of the incretin hormone,
GLP-1, which has a profound insulinotropic action, coupled to
the improved insulin sensitivity resulting from weight loss. The
effect of bariatric surgery upon weight loss is less clear. It is pos-
sible that the acute calorie restriction which occurs immediately
post-surgery, coupled with a beneﬁcial hormonal milieu promotes
weight loss which, unusually, can be maintained over the long-
term. This may, at least in part, be related to sustained increases in
satiety-promoting peptides (GLP-1, GIP, PYY3–36, oxyntomodulin,
gastrin) and reductions in hunger-promoting factors (ghrelin).
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Glossary
CCK: Cholecystokinin
DPP-IV: Dipeptidyl-peptidase-IV
GCGR: Glucagon receptor
GHSR: Growth hormone secretagogue receptor
GIP: Gastric inhibitory peptide
GLP-1: Glucagon like peptide-1
GLP1R: Glucagon like peptide-1 receptor
GOAT: Ghrelin-O-acyltransferase
HOMA: Homeostasis model assessment
PP: Pancreatic polypeptide
PYY: Peptide YYVIP: Vasoactive intestinal polypeptide
